Treatable trait in COPD: is LVDD the potential next?
- 13 October 2026
- journal article
- Published by Elsevier in Respiratory Medicine
- Vol. 264
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Does Treatment of Left Ventricular Diastolic Dysfunction in Chronic Obstructive Pulmonary Disease Matter: An Appraisal from an Open Prospective Real-world Observation with Use of DapagliflozinThe Indian Journal of Chest Diseases and Allied Sciences, 2026
- Echocardiographic Evidence of Left Ventricular Dysfunction in COPD: Relationship with Disease SeverityMedicina, 2025
- Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of EchocardiographyJournal of the American Society of Echocardiography, 2025
- Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert ConsensusJournal of Clinical Medicine, 2024
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection FractionNew England Journal of Medicine, 2022
- Treatable Traits in COPD – A Proposed ApproachInternational Journal of Chronic Obstructive Pulmonary Disease, 2021
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine, 2021
- Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failureCardiovascular Diabetology, 2018
- High Prevalence of Left Ventricle Diastolic Dysfunction in Severe COPD Associated with A Low Exercise Capacity: A Cross-Sectional StudyPLOS ONE, 2013